Crystagen
Also known as: Glu-Asp-Pro
A Khavinson tripeptide (Glu-Asp-Pro) developed in Russia as a tissue-specific bioregulator targeting the thymus and broader immune system. Promoted for age-related immune decline (immunosenescence), recovery from immunosuppressive treatments, and as a general immune support during the cold and flu season. Within the same Khavinson family as thymalin and thymosin alpha-1, both already in your database.
Dosage
Fixed dose: 100-200 mg oral daily for 10-30 day cycles
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Half-Life
Approximately 30 minutes (acute pharmacology); proposed gene-expression effects outlast plasma exposure
Half-Life Calculator →Administration
Oral capsule or subcutaneous injection (cycled)
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Immune Support
Khavinson tripeptide targeting thymic function and T-cell maturation pathways.
Thymic Function
Russian research suggests support for age-related thymic involution.
Lymphocyte Modulation
Reported effects on lymphocyte chromatin organisation and immune cell maturation.
Mechanism of Action
Crystagen is a short Khavinson tripeptide (Glu-Asp-Pro) positioned as the immune and thymus-targeted bioregulator within the wider Khavinson peptide family. The proposed mechanism follows the standard family framework: short peptides interact with gene promoter sequences in thymic and lymphocyte cell nuclei, modulating expression of genes involved in T cell maturation, cytokine production, and broader immune regulation.
Proposed effects include support for thymic function — particularly relevant given the well-documented age-related thymic involution that contributes to immunosenescence in older adults — alongside modulation of lymphocyte chromatin organisation and immune cell maturation pathways. Russian research has reported crystagen-induced improvements in lymphocyte counts, T helper cell function, and clinical recovery from infections in elderly populations and in patients recovering from immunosuppressive treatments. The peptide is often used alongside thymalin (a related thymic peptide preparation also in this database) as part of broader Khavinson immune-support protocols.
As with the rest of the Khavinson family, the efficacy evidence base sits within Russian gerontology and immunology research with limited independent Western validation. Crystagen is not validated as a treatment for primary immunodeficiency, HIV-related immune dysfunction, or other formally diagnosed immune conditions, and should not displace evidence-based immune therapy. The brief plasma half-life (around 30 minutes) reflects the proposed model of transient signalling triggering longer-lasting transcriptional changes in immune cell populations.
Regulatory Status
Not FDA approved. Registered in Russia as a peptide bioregulator and used in Russian clinical immunology and gerontology practice. Available internationally through Khavinson-affiliated suppliers.
Risks & Safety
Common
generally reported as well tolerated.
Serious
very limited Western clinical data; theoretical concern with use in autoimmune disease (immune-modulating peptides may unpredictably affect autoimmune activity).
Rare
allergic reactions. Should not replace evidence-based immune therapy in serious immunodeficiency.
Compare Crystagen With
Research Papers
1Published: January 1, 2014
AI Summary
In aging spleen, Crystagen activates B-cells of the immune system, complementing the T-helper effects of Vilon and R-1. Unlike the other peptides studied, Crystagen does not drive cell renewal in the aging spleen.
Frequently Asked Questions
What is Crystagen?
A Khavinson tripeptide (Glu-Asp-Pro) developed in Russia as a tissue-specific bioregulator targeting the thymus and broader immune system. Promoted for age-related immune decline (immunosenescence), recovery from immunosuppressive treatments, and as a general immune support during the cold and flu season. Within the same Khavinson family as thymalin and thymosin alpha-1, both already in your database.
What is Crystagen used for?
A Khavinson tripeptide (Glu-Asp-Pro) developed in Russia as a tissue-specific bioregulator targeting the thymus and broader immune system. Promoted for age-related immune decline (immunosenescence), recovery from immunosuppressive treatments, and as a general immune support during the cold and flu season. Within the same Khavinson family as thymalin and thymosin alpha-1, both already in your database.
What is the dosage for Crystagen?
Oral (capsule): 100-200 mg once daily for 10-30 day cycles, repeated 2-3 times per year. Subcutaneous injection: 1-5 mg per dose, alternate days for 10-20 day cycles. Standard Khavinson cycling protocol.
What are the side effects of Crystagen?
Common: generally reported as well tolerated. Serious: very limited Western clinical data; theoretical concern with use in autoimmune disease (immune-modulating peptides may unpredictably affect autoimmune activity). Rare: allergic reactions. Should not replace evidence-based immune therapy in serious immunodeficiency.
How does Crystagen work?
Crystagen is a short Khavinson tripeptide (Glu-Asp-Pro) positioned as the immune and thymus-targeted bioregulator within the wider Khavinson peptide family. The proposed mechanism follows the standard family framework: short peptides interact with gene promoter sequences in thymic and lymphocyte cell nuclei, modulating expression of genes involved in T cell maturation, cytokine production, and broader immune regulation. Proposed effects include support for thymic function — particularly relevant given the well-documented age-related thymic involution that contributes to immunosenescence in older adults — alongside modulation of lymphocyte chromatin organisation and immune cell maturation pathways. Russian research has reported crystagen-induced improvements in lymphocyte counts, T helper cell function, and clinical recovery from infections in elderly populations and in patients recovering from immunosuppressive treatments. The peptide is often used alongside thymalin (a related thymic peptide preparation also in this database) as part of broader Khavinson immune-support protocols. As with the rest of the Khavinson family, the efficacy evidence base sits within Russian gerontology and immunology research with limited independent Western validation. Crystagen is not validated as a treatment for primary immunodeficiency, HIV-related immune dysfunction, or other formally diagnosed immune conditions, and should not displace evidence-based immune therapy. The brief plasma half-life (around 30 minutes) reflects the proposed model of transient signalling triggering longer-lasting transcriptional changes in immune cell populations.
How is Crystagen administered?
Crystagen is administered via oral capsule or subcutaneous injection (cycled).
What is the half-life of Crystagen?
The half-life of Crystagen is Approximately 30 minutes (acute pharmacology); proposed gene-expression effects outlast plasma exposure.
Is Crystagen legal?
Not FDA approved. Registered in Russia as a peptide bioregulator and used in Russian clinical immunology and gerontology practice. Available internationally through Khavinson-affiliated suppliers.
Sources. This profile is built from peer-reviewed papers indexed on PubMed, FDA-approved labelling where available, and published clinical guidelines. The 1 primary sources used are listed in the Research Papers section above, each linked to its PubMed entry. See our editorial standards for how we research and review peptide profiles.
Last reviewed. by the Peptide Reference Editorial Team. Spot an error? Email a correction.
Not medical advice. Information on this page is for educational and research reference only. Many peptides covered are not approved for human use. See our full medical disclaimer.
Related Peptides
AEDG Peptide
A tetrapeptide (Ala-Glu-Asp-Gly) identical to Epithalon's core active sequence — effectively the same compound. Studied for telomerase activation and pineal gland regulation, promoting melatonin production and potentially slowing cellular aging through telomere maintenance. Part of the Khavinson bioregulator peptide family developed in St. Petersburg.
Bronchogen
A Khavinson tetrapeptide (Ala-Glu-Asp-Leu) developed in Russia as a tissue-specific bioregulator targeting the lungs and respiratory tract. Promoted for chronic respiratory conditions, age-related decline in lung function, and recovery from respiratory illness. Like the other Khavinson cytamins, the evidence base is dominated by Russian research and not independently validated in Western clinical practice.
CJC-1295 (no DAC)
One of the most popular growth hormone peptides, often called Mod GRF 1-29. Instead of injecting growth hormone directly, this tells your pituitary gland to release more of its own GH naturally. This is considered healthier than injecting GH directly because your body keeps its normal feedback systems intact. Usually combined with Ipamorelin for much stronger effects — the two work together better than either alone.
CJC-1295 + Ipamorelin
The most commonly prescribed peptide combination in anti-aging and regenerative medicine. Pairs the GHRH analogue CJC-1295 (Mod GRF 1-29) with the selective ghrelin-mimetic Ipamorelin for synergistic, pulsatile growth hormone release. Exploits two complementary signaling pathways — cAMP (GHRH) and calcium/PLC (ghrelin receptor) — to amplify GH pulses while maintaining minimal side effects.